Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:15 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU
NCT02343575 · Stanford University · PHASE4 · terminated · last registry update 2019-06-26 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “We did not recruit the research assistant and terminated the study” | – | Registry record, Stanford University |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ALDH5A1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2020-06-11Results posted on the registry: University of South Florida, quetiapine SR + divalproex sodium ER (NCT00579280)
- 2020-05-18Also stopped (withdrawn): Johns Hopkins University, valproic acid (NCT00181220)
- 2020-03-27Results posted on the registry: Food and Drug Administration (FDA), Oxcarbazepine (brand name vs generic drugs) + Divalproex Sodium (brand name vs generic drugs) (NCT02707965)
- 2020-02-28Results posted on the registry: University of Virginia, Fosphenytoin + Levetiracetam (NCT01960075)
- 2020-02-25Results posted on the registry: M.D. Anderson Cancer Center, Placebo + Valproic Acid (VPA) (NCT01900730)
- 2020-02-25Also stopped (terminated): M.D. Anderson Cancer Center, Placebo + Valproic Acid (VPA) (NCT01900730)
- 2020-02-18Phase 3 first posted: Johns Hopkins University, Absence epilepsy medications (NCT04274179)
- 2020-02-10Results posted on the registry: Washington University School of Medicine, Valproate + Placebo (NCT00167934)
- 2019-10-21Also stopped (terminated): OPKO Health, Inc., ELND005 + Lamotrigine (NCT01674010)
- 2019-10-09Results posted on the registry: Gregory Jicha, 323-5550, Valproic Acid + Placebo (NCT01729598)
- 2019-09-16Results posted on the registry: Organon and Co, Asenapine + Placebo (NCT00145470)
- 2019-09-11Results posted on the registry: University of California, San Diego, divalproex ER + quetiapine (NCT00397020)
- 2019-07-29Phase 3 first posted: National Cheng-Kung University Hospital, Memantine or placebo (NCT04035798)
- 2019-07-17Results posted on the registry: University Hospitals Cleveland Medical Center, Divalproex Sodium ER + Placebo (NCT00194116)
- 2018-12-06Results posted on the registry: Montefiore Medical Center, Divalproex sodium + Placebo (NCT00211757)
- 2018-10-25Results posted on the registry: Duke University, Valproic Acid (NCT01928849)
- 2018-09-28Results posted on the registry: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, valproic acid (NCT00670046)
- 2018-09-28Also stopped (terminated): Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, valproic acid (NCT00670046)
- 2018-08-14Results posted on the registry: Weill Medical College of Cornell University, Lithium (LI) + Divalproex (DV) (NCT00254488)
- 2018-08-07Results posted on the registry: Gruppo Italiano Malattie EMatologiche dell'Adulto, 5-Azacytidine + Valproic Acid (NCT00439673)
- 2018-07-17Results posted on the registry: Palo Alto Veterans Institute for Research, Divalproex-extended release (DVP-ER) + Lithium (NCT00183443)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision